Magenkarzinom beim alten und geriatrischen Patienten

  • Nadine Schulte
  • Matthias Ebert
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)


Das Magenkarzinom tritt in höherem Alter häufiger auf, so dass bei steigender Lebenserwartung die Behandlung des geriatrischen onkologischen Patienten zunehmend wichtig wird. Die aus Studien etablierten Konzepte repräsentieren häufig nicht die Besonderheiten im Alter. Anhand verschiedener Studien bei älteren Patienten sowie Subgruppenanalysen und gepoolten Analysen soll im folgenden Kapitel die Evidenz der Therapie beim Magenkarzinom für ältere Patienten genauer beleuchtet werden.


  1. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442CrossRefPubMedGoogle Scholar
  2. Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S et al (2013) The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer 49:835–842CrossRefPubMedGoogle Scholar
  3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial Investigators et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697CrossRefPubMedGoogle Scholar
  4. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069CrossRefPubMedGoogle Scholar
  5. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G et al (2005) Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 16:1488–1497CrossRefPubMedGoogle Scholar
  6. Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM et al (2013) A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer 16:411–419CrossRefPubMedGoogle Scholar
  7. Choi IS, Oh DY, Kim BS, Lee KW, Kim JH, Lee JS (2007) Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat 39:99–103CrossRefPubMedPubMedCentralGoogle Scholar
  8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20CrossRefPubMedGoogle Scholar
  9. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al (2008) Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRefPubMedGoogle Scholar
  10. Dong N, Jiang W, Li H, Liu Z, Xu X, Wang M (2009) Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol 32:559–563CrossRefPubMedGoogle Scholar
  11. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39CrossRefPubMedGoogle Scholar
  12. Fujiwara S, Noguchi T, Harada K et al (2012) How should we treat gastric cancer in the very elderly? Hepatogastroenterology 59:620–622PubMedGoogle Scholar
  13. Hayashi T, Yoshikawa T, Aoyama T et al (2012) Severity of complications after gastrectomy in elderly patients with gastric cancer. World J Surg 36:2139–2145. CrossRefPubMedGoogle Scholar
  14. Hwang IG, Lee HR, Lee HY, Ji JH, Kang JH, Lee SI et al (2015) First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis. J Clin Oncol 33(suppl), abstr4051Google Scholar
  15. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J et al (2010) Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol 36:601–606CrossRefPubMedPubMedCentralGoogle Scholar
  16. Jeong SH, Ahn HS, Yoo MW et al (2010) Increased morbidity rates in patients with heart disease or chronic liver disease following radical gastric surgery. J Surg Oncol 101:200–204PubMedGoogle Scholar
  17. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS (2014) Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat 46:124–130CrossRefPubMedPubMedCentralGoogle Scholar
  18. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673CrossRefPubMedGoogle Scholar
  19. Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T et al (2010) Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol 65:1093–1099CrossRefPubMedGoogle Scholar
  20. Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T et al (2010) Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology 78:54–61CrossRefPubMedGoogle Scholar
  21. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY et al (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99:584–590CrossRefPubMedPubMedCentralGoogle Scholar
  22. Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, Wang MY (2008) Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 31:259–263CrossRefPubMedGoogle Scholar
  23. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, CLASSIC Trial Investigators et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15:1389–1396CrossRefPubMedGoogle Scholar
  24. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D (2009) Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20:1529–1534CrossRefPubMedGoogle Scholar
  25. Pauligk C et al (2015) Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: data from the phase II part of the FLOT4 phase III study of the AIO. J Clin Oncol 33(Suppl), abstr 4016Google Scholar
  26. Pisanu A, Montisci A, Piu S et al (2007) Curative surgery for gastric cancer in the elderly: treatment decisions, surgical morbidity, mortality, prognosis and quality of life. Tumori 93:478–484PubMedGoogle Scholar
  27. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefPubMedGoogle Scholar
  28. Takeshita H, Ichikawa D, Komatsu S et al (2013) Surgical outcomes of gastrectomy for elderly patients with gastric cancer. World J Surg 37:2891–2898. CrossRefPubMedGoogle Scholar
  29. Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M et al (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 42:827–834CrossRefPubMedGoogle Scholar
  30. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev CD004064Google Scholar
  31. Watanabe M, Iwatsuki M, Iwagami S et al (2012) Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg 36:1632–1639. CrossRefPubMedGoogle Scholar
  32. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol 15:1224–1235CrossRefPubMedGoogle Scholar
  33. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721CrossRefPubMedGoogle Scholar

Copyright information

© © Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  1. 1.II. Medizinische KlinikUniversitätsmedizin MannheimMannheimDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations